Get more information on Nuclear Medicine Market - Request Sample Report
The Nuclear Medicine Market Size was valued at USD 11.1 billion in 2023 and is expected to reach USD 38.8 billion by 2032 and grow at a CAGR of 15% over the forecast period 2024-2032.
Rising cancer and cardiovascular diseases, an increase in preference toward non-invasive diagnostic methods, and the development of novel radiopharmaceuticals are accelerating the nuclear medicine market growth. The World Nuclear Association Analysis 2024 estimates around 50 million nuclear medicine procedures a year globally and the demand for radioisotopes increases by about 5% a year. An increase in the applications of nuclear medicine in diagnostics as well as therapeutics further accounts for the growth in demand primarily due to the substantial rise in chronic disease incidence. The speed of increase in the number of cancer cases across the US is exhibited in the American Cancer Society's news release, which states that the number of new cancer cases in the US was 1.95 million in 2023 but is 2 million this year (2024). Likewise, in Canada, the number of new cancer cases rose in 2023 to 239,000, up from 233,000 in 2022, according to Canadian Cancer Statistics. This increase in cancer will lead to an increased demand for more diagnostic and therapeutic nuclear medicine procedures.
In addition, the expansion of the market is being assisted by government programs and spending on healthcare infrastructure. As an example, the National Institutes of Health (NIH) in the US has steadily increased funding for nuclear medicine research, recognizing it as a complementary avenue for advancing personalized medicine approaches. Innovations in radioligand design have led to the creation of agents that selectively bind to cancer markers, optimizing treatment efficacy while minimizing side effects. Furthermore, the incorporation of artificial intelligence and machine learning in nuclear medicine imaging is increasing the efficiency and accuracy of these medical images which in turn boosting the growth of the nuclear medicine market.
Drivers
The increasing incidence of conditions such as cancer and cardiovascular diseases drives the demand for nuclear medicine diagnostics and treatments.
Innovations in imaging technologies and radiopharmaceuticals enhance the effectiveness and adoption of nuclear medicine procedures.
An aging global population leads to a higher prevalence of age-related diseases, increasing the need for nuclear medicine services.
The nuclear medicine market is primarily being driven by the rising incidence of chronic diseases, especially cancer and cardiovascular diseases. The World Health Organization (WHO) reported that in 2023, nearly 10 million people died of cancer worldwide, with lung, colorectal, and breast cancers being the most common. These alarming statistics highlight the urgent need for better diagnostic and therapeutic tools like nuclear medicine. Radiopharmaceuticals are used in nuclear medicine for diagnosis and treatment of diseases at the molecular level. For example, imaging with positron emission tomography (PET) and single-photon emission computed tomography (SPECT) is commonly used for detecting the site of tumors, tracking tumor progression, and assessing treatment response for cancer treatment. For example, an FDG PET scan can identify tumors that are consuming more glucose than normal, indicating that they are likely becoming active malignancies, helping oncologists tailor the treatment plan.
Cardiovascular diseases are still the leading cause of death in the world, with around 18 million deaths a year, according to the American Heart Association. Nuclear cardiology techniques, including myocardial perfusion imaging (MPI), assess blood flow to the heart muscle and detection of coronary artery disease to facilitate timely interventions. The increasing role of nuclear medicine is also evidenced by innovations in the field of radiopharmaceuticals, including the development of targeted alpha therapies (TATs) directed to metastatic cancers. Together with the increasing burden of diseases, these advancements are driving the adoption of nuclear medicine as one of the essential healthcare services.
Restraints:
The significant expenses associated with nuclear medicine procedures and equipment can limit accessibility and adoption.
Supply chain challenges and the short half-life of certain isotopes can hinder the consistent availability of necessary materials.
A major limitation of the nuclear medicine market is the depletion of radioisotopes necessary for diagnostic imaging and therapy. Several popular isotopes, including Technetium-99m, have short half-lives requiring continuous production and rapid transport to hospitals. These isotopes are produced in very few locations in North America and the rest of the world, often in nuclear reactors or cyclotrons. A disruption in reactor operations, maintenance schedules, or some geopolitical factor affecting the source can cause a supply shortage, causing a delay in patient treatments.
Moreover, stringent regulation on the transportation and handling of radioactive materials adds to and challenges the supply chain. The costs to establish new production facilities and the technical expertise are also significant hurdles. Such a limited supply tends to restrict the availability of nuclear medicine (NMI), especially in the developing part of this world with inadequate infrastructure which shows the need for investment in isotope production technologies and logistical aspects to serve the increasing demands of healthcare.
By product
In 2023, the nuclear medicine market was dominated by the diagnostics segment with 74% of the share. The large share of the market can be attributed to a few factors, mostly because diagnostic nuclear medicine exams are performed in almost all medical specialties. In 2023, the Society of Nuclear Medicine & Nuclear Imaging estimated that more than 20 million nuclear medicine procedures were performed each year in the U.S. The large share of this segment is attributed to the rising number of chronic conditions that need advanced imaging methods for accurate diagnosis and treatment planning. For example, the World Nuclear Association Analysis 2024 stated radioisotope needed for diagnostics increases by approximately 5 percent every year. The increasing application of SPECT and PET in oncology, cardiology, and neurology are contributing to this growth. The growth can be attributed to the presence of a broad spectrum of radiotracers available for the diagnosis of tumors and developed imaging equipment. In addition, the non-invasiveness of nuclear medicine diagnostics is one of the main reasons for their preference among patients and doctors. The recurrent approval of novel diagnostic radiopharmaceuticals by the U.S. Food and Drug Administration (FDA) in turn will contribute majorly to expanding the segment of particularly diagnostic radiopharmaceuticals market share. In August 2024, a PET radiotracer for imaging patients with suspected or confirmed cardiac amyloidosis was designated by the FDA as a breakthrough therapy, reflecting rapid innovations in this area.
By Application
The Urology segment dominated the market with a market share of 22% in 2023. The largest share of this market is due to the high incidence of urological disorders, with prostate cancer being the most common cancer in men worldwide. According to the American Cancer Society, 1 in 5 new cancer diagnoses are prostate cancer diagnoses in men in the United States. The Role of Nuclear Medicine in the Diagnosis and Treatment of Prostate Cancer Nuclear medicine is integral to the detection and treatment of prostate cancer, especially in the era of PET/CT and targeted radionuclide therapy. Novel radiopharmaceuticals for prostate cancer, particularly the recent approvals by the U.S. Food and Drug Administration, including Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in 2022 have greatly increased the application of nuclear medicine in the urology field. With this approval, there was a significant step forward to help improve outcomes for patients with metastatic castration-resistant prostate cancer, reinforcing the increasing role of nuclear medicine in urological oncology. In addition, the rising use of combination and the ranostic approaches in urology by the use of radiopharmaceuticals which has recipes for both diagnostic imaging and targeted therapy is expected to contribute considerably to the dominant share of the segment. The National Cancer Institute has noted an increasing trend of employing nuclear medicine modalities for the long-term care of urological malignancies, specifically for staging and treatment planning.
By End Use
In 2023, the hospital's segment accounted for the largest market 54% of the market. The leading position is mainly driven by several factors, primarily by the comprehensive nature of hospital facilities that can provide a complete variety of nuclear medicine services. The Society of Nuclear Medicine & Nuclear Imaging has historical data showing hospitals have traditionally been the site of nuclear medicine procedures. More than 50% of all nuclear medicine procedures are performed in hospitals in the USA as of 2020. Hospitals remained the market's top player and this trend continued. The market share of hospitals is also high due to developed infrastructure facilities of hospitals for the processing of complex nuclear medicine equipment and radioactive materials. In addition, hospitals have a more comprehensive infrastructure to deal with the entire range of patient care from diagnosis to treatment to follow-up, which is particularly vital in nuclear medicine applications. Nuclear medicine is typically performed in a hospital but is also done in some outpatient settings, which was reflected in data from the U.S. Nuclear Regulatory Commission for years before 1995, which suggested that most licensed facilities for nuclear medicine were associated with hospitals. Moreover, with growing focus on centralization of the healthcare delivery system, particularly for complicated procedures incorporating radiopharmaceuticals, is continuing to consolidate the hospital's position in the nuclear medicine market.
The nuclear medicine market was dominated by North America with a market share of nearly 43% in 2023. The regional growth is due to the presence of advanced healthcare infrastructure, with high adoption rates for nuclear medicine technologies and significant investments in research and development. Nuclear medicine applications and innovation in particular have been a leading area for the United States. The Nation produces or uses around fifty percent of the world's supply of medical isotopes, according to the U.S. Department of Energy's National Nuclear Security Administration. This strong production capability integrated with a sound regulatory framework has made North America a leader in the global market.
Asia Pacific remains the fastest-growing region with a high CAGR expected during the forecast period. The growth is likely to follow a strong trajectory owing to factors such as increasing healthcare spending, rising awareness of the applications of nuclear medicine, and increasing prevalence of cancer and cardiovascular diseases in China and India. As an example, in the context of the ongoing healthcare reform in China, the Chinese government has been promoting the development of nuclear medicine. The number of nuclear medicine departments in Chinese hospitals has been increasing by approximately 10% annually recently, according to the National Health Commission of the People's Republic of China. This upsurge is backed by the rampant development of healthcare infrastructure, rising government expenditures in nuclear medicine facilities, and an increased demand for more advanced diagnostic and therapeutic procedures. As an example; Japan is one of the most important countries in the Asia Pacific nuclear medicine market, which has been focusing on the development of novel radiopharmaceuticals and imaging techniques. Owing to Japanese government initiatives encouraging nuclear medicine R&D, the market share in the region is increasing.
Need any customization research on Nuclear Medicine Market - Enquiry Now
In March 2024, Serbia's Ministry of Health and Rosatom State Corporation signed a memorandum of understanding (MoU) to expand bilateral cooperation in the field of nuclear medicine, in a bid to stimulate market expansion.
Bristol Myers Squibb expanded its cancer therapies in December 2023, acquiring RayzeBio for $4.1 billion and its actinium-255 and lutetium-177 therapies.
Key Service Providers/Manufacturers
GE HealthCare (Discovery NM/CT 670, Discovery PET/CT 710)
Siemens Healthineers (Biograph Vision PET/CT, Symbia Intevo SPECT/CT)
Philips Healthcare (Vereos Digital PET/CT, BrightView SPECT)
Canon Medical Systems Corporation (Celesteion PET/CT, Aquilion ONE/GENESIS Edition)
Lantheus Medical Imaging, Inc. (DEFINITY, TechneLite)
Bracco Imaging S.p.A (MultiHance, CardioGen-82)
Cardinal Health (Lymphoseek, Zevalin)
Curium (Sodium Iodide I-131, Thallium-201)
Eckert & Ziegler (GalliaPharm, Yttriga)
Nordion (Canada), Inc. (Cobalt-60, Molybdenum-99)
NTP Radioisotopes SOC Ltd. (Fluorodeoxyglucose (FDG), Iodine-131)
Advanced Accelerator Applications (a Novartis company) (Lutathera, NETSPOT)
Jubilant Life Sciences Ltd. (Iodine-131, Molybdenum-99)
Eczacıbaşı-Monrol (FDG, Gallium-68)
Australian Nuclear Science and Technology Organisation (ANSTO) (Technetium-99m, Molybdenum-99)
Shine Technologies (Molybdenum-99, Lutetium-177)
Telix Pharmaceuticals, Inc. (Illuccix, TLX591)
Nordic Nanovector (Betalutin, Humalutin)
Y-mAbs Therapeutics, Inc. (Omburtamab, Naxitamab)
Blue Earth Diagnostics (Axumin, Fluciclovine F-18)
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 11.1 Billion |
| Market Size by 2032 | USD 38.8 Billion |
| CAGR | CAGR of 15% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Diagnostics {SPECT, PET}, Therapeutics {Alpha Emitters, Beta Emitters, Brachytherapy}) • By Application (Cardiology, Neurology, Oncology, Thyroid, Lymphoma, Bone Metastasis, Endocrine Tumor, Pulmonary Scans, Urology, Other) • By End-use (Hospitals, Diagnostic Centers, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | GE HealthCare, Siemens Healthineers, Philips Healthcare, Canon Medical Systems Corporation, Lantheus Medical Imaging, Inc., Bracco Imaging S.p.A, Cardinal Health, Curium, Eckert & Ziegler, Nordion (Canada), Inc., NTP Radioisotopes SOC Ltd., Advanced Accelerator Applications, Jubilant Life Sciences Ltd., Eczacıbaşı-Monrol, Australian Nuclear Science and Technology Organisation (ANSTO), Shine Technologies, Telix Pharmaceuticals, Inc., Nordic Nanovector, Y-mAbs Therapeutics, Inc., Blue Earth Diagnostics |
| Key Drivers | • The increasing incidence of conditions such as cancer and cardiovascular diseases drives the demand for nuclear medicine diagnostics and treatments. • Innovations in imaging technologies and radiopharmaceuticals enhance the effectiveness and adoption of nuclear medicine procedures. |
| Restraints | • Establishing and maintaining cleanrooms involve significant expenses, including specialized HVAC systems and energy consumption, which can deter adoption. • Compliance with rigorous standards demands continuous monitoring and validation, posing challenges for manufacturers. |
Ans. The projected market size for the Nuclear Medicine Market is USD 38.8 Billion by 2032.
Ans: The major key players in the market are GE HealthCare, Siemens Healthineers, Philips Healthcare, Canon Medical Systems Corporation, Lantheus Medical Imaging, Inc., Bracco Imaging S.p.A, Cardinal Health, Curium, Eckert & Ziegler, Nordion (Canada), Inc., NTP Radioisotopes SOC Ltd., Advanced Accelerator Applications, and others in final report.
Ans: The Nuclear Medicine Market size is to grow at a CAGR of 15% over the forecast period 2024-2032.
Ans: North America region dominate the Nuclear Medicine Market.
Ans: Radiopharmaceuticals are used in sensory processing
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends, (2023), by Region
5.3 Device Volume, by Region (2020-2032)
5.4 Healthcare Spending, by Region, (Government, Commercial, Private, Out-of-Pocket), 2023
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Nuclear Medicine Market Segmentation, By Product
7.1 Chapter Overview
7.2 Diagnostics
7.2.1 Diagnostics Market Trends Analysis (2020-2032)
7.2.2 Diagnostics Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.3 SPECT
7.2.3.1 SPECT Market Trends Analysis (2020-2032)
7.2.3.2 SPECT Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.3.3 TC-99m
7.2.3.3.1 TC-99m Market Trends Analysis (2020-2032)
7.2.3.3.2 TC-99m Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.3.4 TL-201
7.2.3.4.1 TL-201 Market Trends Analysis (2020-2032)
7.2.3.4.2 TL-201 Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.3.5 GA-67
7.2.3.5.1 GA-67 Market Trends Analysis (2020-2032)
7.2.3.5.2 GA-67 Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.3.6 I-123
7.2.3.6.1 I-123 Market Trends Analysis (2020-2032)
7.2.3.6.2 I-123 Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.3.7 Others
7.2.3.7.1 Others Market Trends Analysis (2020-2032)
7.2.3.7.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.4 PET
7.2.4.1 PET Market Trends Analysis (2020-2032)
7.2.4.2 PET Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.4.3 F-18
7.2.4.3.1 F-18 Market Trends Analysis (2020-2032)
7.2.4.3.2 F-18 Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.4.4 SR-82/RB-82
7.2.4.4.1 SR-82/RB-82 Market Trends Analysis (2020-2032)
7.2.4.4.2 SR-82/RB-82 Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.4.5 PYLARIFY (piflufolastat F 18)
7.2.4.5.1 PYLARIFY (piflufolastat F 18) Market Trends Analysis (2020-2032)
7.2.4.5.2 PYLARIFY (piflufolastat F 18) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.4.6 Illuccix (gallium Ga 68 gozetotide)
7.2.4.6.1 Illuccix (gallium Ga 68 gozetotide) Market Trends Analysis (2020-2032)
7.2.4.6.2 Illuccix (gallium Ga 68 gozetotide) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.4.7 Others
7.2.4.7.1 Others Market Trends Analysis (2020-2032)
7.2.4.7.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Therapeutics
7.3.1 Therapeutics Market Trends Analysis (2020-2032)
7.3.2 Therapeutics Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.3 Alpha Emitters
7.3.3.1 Alpha Emitters Market Trends Analysis (2020-2032)
7.3.3.2 Alpha Emitters Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.3.3 RA-223
7.3.3.3.1 RA-223 Market Trends Analysis (2020-2032)
7.3.3.3.2 RA-223 Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.3.4 Others
7.3.3.4.1 Others Market Trends Analysis (2020-2032)
7.3.3.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.4 Beta Emitters
7.3.4.1 Beta Emitters Market Trends Analysis (2020-2032)
7.3.4.2 Beta Emitters Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.4.3 I-131
7.3.4.3.1 I-131 Market Trends Analysis (2020-2032)
7.3.4.3.2 I-131 Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.4.4 Y-90
7.3.4.4.1 Y-90 Market Trends Analysis (2020-2032)
7.3.4.4.2 Y-90 Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.4.5 SM-153
7.3.4.5.1 SM-153 Market Trends Analysis (2020-2032)
7.3.4.5.2 SM-153 Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.4.6 Re-186
7.3.4.6.1 Re-186 Market Trends Analysis (2020-2032)
7.3.4.6.2 Re-186 Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.4.7 Lu-177
7.3.4.7.1 Lu-177 Market Trends Analysis (2020-2032)
7.3.4.7.2 Lu-177 Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.4.8 Others
7.3.4.8.1 Others Market Trends Analysis (2020-2032)
7.3.4.8.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.5 Brachytherapy
7.3.5.1 Brachytherapy Market Trends Analysis (2020-2032)
7.3.5.2 Brachytherapy Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.5.3 Cesium-131
7.3.5.3.1 Cesium-131 Market Trends Analysis (2020-2032)
7.3.5.3.2 Cesium-131 Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.5.4 Iodine-125
7.3.5.4.1 Iodine-125 Market Trends Analysis (2020-2032)
7.3.5.4.2 Iodine-125 Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.5.5 Palladium-103
7.3.5.5.1 Palladium-103 Market Trends Analysis (2020-2032)
7.3.5.5.2 Palladium-103 Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.5.6 Iridium-192
7.3.5.6.1 Iridium-192 Market Trends Analysis (2020-2032)
7.3.5.6.2 Iridium-192 Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.5.7 Others
7.3.5.7.1 Others Market Trends Analysis (2020-2032)
7.3.5.7.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Nuclear Medicine Market Segmentation, By Application
8.1 Chapter Overview
8.2 Cardiology
8.2.1 Cardiology Market Trends Analysis (2020-2032)
8.2.2 Cardiology Market Size Estimates and Forecasts to 2032 (USD Billion)
8.2.3 SPECT
8.2.3.1 SPECT Market Trends Analysis (2020-2032)
8.2.3.2 SPECT Market Size Estimates and Forecasts to 2032 (USD Billion)
8.2.4 PET
8.2.4.1 PET Market Trends Analysis (2020-2032)
8.2.4.2 PET Market Size Estimates and Forecasts to 2032 (USD Billion)
8.2.5 Therapeutic Applications
8.2.5.1 Therapeutic Applications Market Trends Analysis (2020-2032)
8.2.5.2 Therapeutic Applications Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Neurology
8.3.1 Neurology Market Trends Analysis (2020-2032)
8.3.2 Neurology Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Oncology
8.4.1 Oncology Market Trends Analysis (2020-2032)
8.4.2 Oncology Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Thyroid
8.5.1 Thyroid Market Trends Analysis (2020-2032)
8.5.2 Thyroid Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5.3 SPECT
8.5.3.1 SPECT Market Trends Analysis (2020-2032)
8.5.3.2 SPECT Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5.4 Therapeutic Applications
8.5.4.1 Therapeutic Applications Market Trends Analysis (2020-2032)
8.5.4.2 Therapeutic Applications Market Size Estimates and Forecasts to 2032 (USD Billion)
8.6 Lymphoma
8.6.1 Lymphoma Market Trends Analysis (2020-2032)
8.6.2 Lymphoma Market Size Estimates and Forecasts to 2032 (USD Billion)
8.7 Bone Metastasis
8.7.1 Bone Metastasis Market Trends Analysis (2020-2032)
8.7.2 Bone Metastasis Market Size Estimates and Forecasts to 2032 (USD Billion)
8.8 Endocrine Tumor
8.8.1 Endocrine Tumor Market Trends Analysis (2020-2032)
8.8.2 Endocrine Tumor Market Size Estimates and Forecasts to 2032 (USD Billion)
8.9 Pulmonary Scans
8.9.1 Pulmonary Scans Market Trends Analysis (2020-2032)
8.9.2 Pulmonary Scans Market Size Estimates and Forecasts to 2032 (USD Billion)
8.10 Other
8.10.1 Other Market Trends Analysis (2020-2032)
8.10.2 Other Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Nuclear Medicine Market Segmentation, By End-use
9.1 Chapter Overview
9.2 Hospitals
9.2.1 Hospitals Market Trends Analysis (2020-2032)
9.2.2 Hospitals Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Diagnostic Centers
9.3.1 Diagnostic Centers Market Trends Analysis (2020-2032)
9.3.2 Diagnostic Centers Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Others
9.4.1 Others Market Trends Analysis (2020-2032)
9.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Nuclear Medicine Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.2.3 North America Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.2.4 North America Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.2.5 North America Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.2.6.2 USA Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.2.6.3 USA Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.2.7.2 Canada Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.2.7.3 Canada Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.2.8.2 Mexico Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.2.8.3 Mexico Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Nuclear Medicine Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.1.3 Eastern Europe Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.3.1.4 Eastern Europe Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.1.5 Eastern Europe Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.1.6 Poland
10.3.1.6.1 Poland Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.3.1.6.2 Poland Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.1.6.3 Poland Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.1.7 Romania
10.3.1.7.1 Romania Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.3.1.7.2 Romania Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.1.7.3 Romania Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.3.1.8.2 Hungary Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.1.8.3 Hungary Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.1.9 Turkey
10.3.1.9.1 Turkey Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.3.1.9.2 Turkey Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.1.9.3 Turkey Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.3.1.10.2 Rest of Eastern Europe Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.1.10.3 Rest of Eastern Europe Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Nuclear Medicine Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.2.3 Western Europe Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.3.2.4 Western Europe Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.5 Western Europe Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.2.6 Germany
10.3.2.6.1 Germany Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.3.2.6.2 Germany Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.6.3 Germany Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.2.7 France
10.3.2.7.1 France Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.3.2.7.2 France Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.7.3 France Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.2.8 UK
10.3.2.8.1 UK Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.3.2.8.2 UK Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.8.3 UK Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.2.9 Italy
10.3.2.9.1 Italy Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.3.2.9.2 Italy Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.9.3 Italy Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.2.10 Spain
10.3.2.10.1 Spain Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.3.2.10.2 Spain Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.10.3 Spain Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.3.2.11.2 Netherlands Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.11.3 Netherlands Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.3.2.12.2 Switzerland Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.12.3 Switzerland Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.2.13 Austria
10.3.2.13.1 Austria Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.3.2.13.2 Austria Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.13.3 Austria Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.3.2.14.2 Rest of Western Europe Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.14.3 Rest of Western Europe Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Nuclear Medicine Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.4.3 Asia Pacific Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.4.4 Asia Pacific Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.5 Asia Pacific Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.4.6.2 China Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.6.3 China Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.4.7.2 India Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.7.3 India Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.4.8.2 Japan Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.8.3 Japan Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.4.9.2 South Korea Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.9.3 South Korea Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.4.10 Vietnam
10.4.10.1 Vietnam Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.4.10.2 Vietnam Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.10.3 Vietnam Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.4.11 Singapore
10.4.11.1 Singapore Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.4.11.2 Singapore Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.11.3 Singapore Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.4.12 Australia
10.4.12.1 Australia Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.4.12.2 Australia Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.12.3 Australia Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.4.13.2 Rest of Asia Pacific Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.13.3 Rest of Asia Pacific Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Nuclear Medicine Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.1.3 Middle East Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.5.1.4 Middle East Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.1.5 Middle East Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.5.1.6 UAE
10.5.1.6.1 UAE Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.5.1.6.2 UAE Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.1.6.3 UAE Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.5.1.7.2 Egypt Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.1.7.3 Egypt Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.5.1.8.2 Saudi Arabia Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.1.8.3 Saudi Arabia Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.5.1.9.2 Qatar Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.1.9.3 Qatar Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.5.1.10.2 Rest of Middle East Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.1.10.3 Rest of Middle East Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Nuclear Medicine Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.2.3 Africa Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.5.2.4 Africa Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.2.5 Africa Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.5.2.6.2 South Africa Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.2.6.3 South Africa Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.5.2.7.2 Nigeria Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.2.7.3 Nigeria Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.5.2.8.2 Rest of Africa Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.2.8.3 Rest of Africa Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Nuclear Medicine Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.6.3 Latin America Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.6.4 Latin America Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.6.5 Latin America Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.6.6.2 Brazil Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.6.6.3 Brazil Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.6.7.2 Argentina Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.6.7.3 Argentina Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.6.8 Colombia
10.6.8.1 Colombia Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.6.8.2 Colombia Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.6.8.3 Colombia Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Nuclear Medicine Market Estimates and Forecasts, By Product (2020-2032) (USD Billion)
10.6.9.2 Rest of Latin America Nuclear Medicine Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.6.9.3 Rest of Latin America Nuclear Medicine Market Estimates and Forecasts, By End-use (2020-2032) (USD Billion)
11. Company Profiles
11.1 GE HealthCare
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 SWOT Analysis
11.2 Siemens Healthineers
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 SWOT Analysis
11.3 Philips Healthcare
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 SWOT Analysis
11.4 Canon Medical Systems Corporation
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 SWOT Analysis
11.5 Lantheus Medical Imaging, Inc.
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 SWOT Analysis
11.6 Bracco Imaging S.p.A
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 SWOT Analysis
11.7 Cardinal Health
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 SWOT Analysis
11.8 Eckert & Ziegler
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 SWOT Analysis
11.9 Nordion (Canada), Inc.
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 SWOT Analysis
11.10 NTP Radioisotopes SOC Ltd.
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Product
Diagnostics
SPECT
TC-99m
TL-201
GA-67
I-123
Others
PET
F-18
SR-82/RB-82
PYLARIFY (piflufolastat F 18)
Illuccix (gallium Ga 68 gozetotide)
Others
Therapeutics
Alpha Emitters
RA-223
Others
Beta Emitters
I-131
Y-90
SM-153
Re-186
Lu-177
Others
Brachytherapy
Cesium-131
Iodine-125
Palladium-103
Iridium-192
Others
By Application
Cardiology
SPECT
PET
Therapeutic Applications
Neurology
Oncology
Thyroid
SPECT
Therapeutic Applications
Lymphoma
Bone Metastasis
SPECT
Therapeutic Applications
Endocrine Tumor
Pulmonary Scans
Urology
Other
By End-use
Hospitals
Diagnostic Centers
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
REGIONAL COVERAGE:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Telepsychiatry Market was valued at USD 7.34 billion in 2023 and is expected to reach USD 41.59 billion by 2032, growing at a CAGR of 20.81% from 2024 to 2032
The Injectable Cytotoxic Drugs Market size was USD 19.58 Billion in 2023 and is expected to Reach USD 38.15 Billion by 2032 and grow at a CAGR of 6.9% over the forecast period of 2024-2032.
The Pharmaceutical Cartridges Market Size was valued at USD 1.41 Billion in 2023 and is expected to reach USD 2.86 Billion by 2032 and grow at a CAGR of 8.57% over the forecast period 2024-2032.
Healthcare Claims Management Market was valued at USD 15.01 Bn in 2023 and is expected to reach USD 24.93 Bn by 2032, growing at a CAGR of 5.85% from 2024-2032.
Dental Lasers Market was estimated at USD 339.95 million in 2023 and is expected to reach USD 664.60 million by 2032, growing at a CAGR of 7.76% from 2024-2032.
The Cosmeceuticals Market Size was valued at USD 63.63 Billion in 2023, and is expected to reach USD 142.52 Billion by 2032, and grow at a CAGR of 9.84%.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
